

# Bram De Wilde

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7282607/publications.pdf>

Version: 2024-02-01

36  
papers

2,787  
citations

516710

16  
h-index

414414

32  
g-index

41  
all docs

41  
docs citations

41  
times ranked

5786  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	21.4	1,186
2	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. <i>Nature</i> , 2015, 526, 700-704.	27.8	478
3	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , 2018, 362, 1165-1170.	12.6	213
4	Emergence of New <i>ALK</i> Mutations at Relapse of Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2727-2734.	1.6	176
5	Targeted Expression of Mutated <i>ALK</i> Induces Neuroblastoma in Transgenic Mice. <i>Science Translational Medicine</i> , 2012, 4, 141ra91.	12.4	147
6	Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients. <i>Clinical Cancer Research</i> , 2017, 23, 6305-6314.	7.0	113
7	The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review. <i>European Journal of Pediatrics</i> , 2020, 179, 191-202.	2.7	55
8	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. <i>European Journal of Cancer</i> , 2020, 136, 52-68.	2.8	42
9	Practical Tools to Implement Massive Parallel Pyrosequencing of PCR Products in Next Generation Molecular Diagnostics. <i>PLoS ONE</i> , 2011, 6, e25531.	2.5	40
10	Massively parallel sequencing for early molecular diagnosis in Leber congenital amaurosis. <i>Genetics in Medicine</i> , 2012, 14, 576-585.	2.4	39
11	Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. <i>Oncotarget</i> , 2016, 7, 1960-1972.	1.8	26
12	Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait. <i>Epigenetics</i> , 2016, 11, 761-771.	2.7	24
13	Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study. <i>Epigenetics</i> , 2021, 16, 196-208.	2.7	23
14	Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome. <i>Epigenetics</i> , 2021, 16, 797-807.	2.7	21
15	The ETS transcription factor <i>ETV5</i> is a target of activated <i>ALK</i> in neuroblastoma contributing to increased tumour aggressiveness. <i>Scientific Reports</i> , 2020, 10, 218.	3.3	20
16	Target enrichment using parallel nanoliter quantitative PCR amplification. <i>BMC Genomics</i> , 2014, 15, 184.	2.8	17
17	<i>ALK</i> positively regulates <i>MYCN</i> activity through repression of <i>HBP1</i> expression. <i>Oncogene</i> , 2019, 38, 2690-2705.	5.9	17
18	The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. <i>European Journal of Cancer</i> , 2022, 160, 12-23.	2.8	16

#	ARTICLE	IF	CITATIONS
19	Complex genetics of radial ray deficiencies: screening of a cohort of 54 patients. <i>Genetics in Medicine</i> , 2013, 15, 195-202.	2.4	15
20	CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients. <i>PLoS ONE</i> , 2014, 9, e114696.	2.5	15
21	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. <i>European Journal of Cancer</i> , 2020, 141, 82-91.	2.8	15
22	RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. <i>Science Advances</i> , 2022, 8, .	10.3	15
23	High-throughput PCR assay design for targeted resequencing using primerXL. <i>BMC Bioinformatics</i> , 2017, 18, 400.	2.6	13
24	Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103564.	4.4	12
25	The mutational landscape of <i>MYCN</i> , <i>Lin28b</i> and <i>ALK</i> <i>F1174L</i> driven murine neuroblastoma mimics human disease. <i>Oncotarget</i> , 2018, 9, 8334-8349.	1.8	6
26	Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1867-1870.	1.5	5
27	Cellular senescence in neuroblastoma. <i>British Journal of Cancer</i> , 2022, 126, 1529-1538.	6.4	5
28	Hypotonia and delayed motor development as an early presentation of Lowe syndrome: case report and literature review. <i>Acta Clinica Belgica</i> , 2019, 74, 460-464.	1.2	4
29	Pinpointing a potential role for <i>CLEC12B</i> in cancer predisposition through familial exome sequencing. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27513.	1.5	3
30	Severe anaphylactic reaction following anti-thymocyte globulin administration in a pediatric stem cell transplantation patient. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 232-234.	0.9	2
31	Cancer Gene Prioritization for Targeted Resequencing Using FitSNP Scores. <i>PLoS ONE</i> , 2012, 7, e31333.	2.5	2
32	From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1286.	2.5	2
33	Chromosome 3p Microsatellite Allelotyping in Neuroblastoma: A Report on the Technical Hurdles. <i>Cancer Investigation</i> , 2009, 27, 857-868.	1.3	0
34	Purpura fulminans: How varicella zoster can result in acquired protein S deficiency. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 146-147.	1.3	0
35	Factors Influencing Change in MCV and Age at Transplantation in the Belgian Sick Cell Disease Registry. <i>Blood</i> , 2021, 138, 4171-4171.	1.4	0
36	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. <i>Neuro-Oncology</i> , 2022, 24, i61-i62.	1.2	0